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SCIENTIFIC LETTER
To the Editor: The aim of this study was to document the
decisions made by the University of Cape Town (UCT)
Research Ethics Committee (REC) and to identify the reasons
for rejection or acceptance of  protocols subject to additional
requirements/conditions. Identifying ethical problems that are
grounds for rejection of protocols can assist in educating
researchers on these issues and facilitate the implementation of
well-designed, socially valuable research. 
The establishment and support of human RECs is considered
a major priority by the Secretary General of the Council for
International Organizations of Medical Sciences (CIOMS).1 The
terms of reference of RECs require the boards ‘to review and
recommend modification, if needed, of research protocols, to
reject irresponsible protocols and to monitor ongoing projects’.2
The UCT REC currently reviews 300 - 400 research protocols
per year originating from UCT or affiliated hospitals. UCT has
not previously documented the number and nature of protocol
acceptances and provisional and absolute rejections by its REC.
Similar studies have been conducted elsewhere but there are
few research overviews of REC stipulations in the literature.3
Audits of practice can provide useful information to
institutions and researchers3 and result in a reduction in
approval time.4 They can also assist academic institutions in
monitoring their faculty research priorities. 
Methods 
We used a retrospective, descriptive study design and analysed
all protocols considered by the REC of UCT from January to
June 2002. Descriptive statistics were used to describe the
numbers, types of studies, etc. 
Data sources included the official application form for ethical
approval, the submitted protocol, the written comments of the
reviewers and the correspondence of the chairperson of the
REC and the principal investigators (PIs).
Approval was obtained from the REC to undertake the study
and access the protocols, respecting the confidentiality of any
proprietary information. 
Results
A total of 197 protocols were reviewed, of which 189 were
included in the analysis; 24% were for contract research (i.e.
research sponsored by commercial sources, such as
pharmaceutical companies), 44.4% for postgraduate degree
purposes and 31% were investigator driven. Ninety-eight
protocols (50%) required resubmission with amendments and
173 protocols (91.5%) were ultimately approved.  The mean
time from submission to final approval of the protocols was 2.0
months (standard deviation (SD) 1.5 months, range 1 - 10
months). There were 254 stipulations, most related to a
favourable risk-benefit ratio (23%) and aspects of informed
consent (24%), followed by problems with scientific validity
(17%), fair subject selection (13%), independent review
(procedural amendments required) (11%) and respect for
persons (10%). There were few stipulations regarding social or
scientific merit (2%). 
HIV/AIDS was the most common condition researched
(13%), followed by sport-related injuries and related exercise
physiology (11%) and conditions affecting the respiratory tract,
including research on asthma and rhinitis (9.5%).
Outcome of submission
Ninety-eight protocols (50%) required resubmission with
amendments. The mean time from submission of the protocol
to communication of the amendments required by the REC was
1.24 months (SD 0.59 months, range 0.27 - 3.4 months).
Ultimately 173 protocols (91.5%) were approved. The mean
time from submission to final approval of the protocols was 2.0
months (SD 1.5 months, range 1 - 10 months). Excessive delay
in approval was due to the PIs having to consult with
sponsors, waiting for South African Medicines Control Council
approval or not submitting all the documentation required.
REC administrative problems, including delayed reviewer
response, caused delays in three cases.
Ethical objections
Frequently more than one ethical objection was raised per
protocol.
Incorrect submission procedure resulted in return of 11% of
the protocols. This included incomplete application forms,
submission without proof of approval from the Medicines
Control Council and inadequate disclosure of financial or other
conflicts of interest. 
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Scientific validity amendments were requested in 22% of the
studies. The Nuremberg Code5 and the Declaration of Helsinki6
state that good scientific methodology is a prerequisite for
ethical justifiability.7 Problems included inadequate definition
of terms, inappropriate research design, poor description of
inclusion criteria, inappropriate use of English measurement
outcomes in subjects from other language groups and
inadequate description of statistical methods. 
The informed consent process was often (20%) the subject of
REC stipulation as in other studies.3 Information sheets were
found to be too technical, badly phrased, poorly translated or
misleading. Inadequate information was the most common
objection (13%). Information regarding the risks, benefits,
alternative treatments available, time commitment, and
potential payment, was frequently missing. Information related
to HIV testing was sometimes found to be inadequate. Several
protocols did not mention the need to obtain assent from
minors and there was often confusion regarding the age of
consent (legally 21 years of age).  
Beneficence or the well-being of the subjects, specifically
safety and subject protection issues, gave rise to 22% of the
objections.  A recurring issue was the insurance cover of
participants. In non-contract research there was concern that
the participant was not covered for any research-related
misadventure on a no-fault basis, apart from the researchers’
professional malpractice insurance. There was considerable
debate on how to proceed with protocols that included
monitoring different aspects of the health and functioning of
people living with HIV but without access to antiretroviral
therapy. PIs were ultimately requested to insert a clause that
they would ensure that the participants in their study would be
given access to antiretroviral therapy if it were to become
available and that any study researching the ‘natural course’ of
the disease would cease.
Justice or equity-related concerns were raised in 12% of
stipulations. The REC insisted that the 2000 version of the
Helsinki declaration be cited (7% of objections). Article 30
states: ‘At the conclusion of the study, every patient entered
into the study should be assured of access to the best proven
prophylactic, diagnostic and therapeutic methods identified by
the study’,6 particularly with regard to the provision of post-
trial drugs where applicable and feasible. Queries were
frequently raised regarding the choice of disadvantaged
subjects or the exclusive use of developing countries, including
South Africa, as subjects/sites for research.  
Confidentiality or autonomy issues were raised in 13% of
cases. Several protocols were rejected as they proposed
recruitment of participants from existing patient records,
without first obtaining permission from the participants.
Others failed to state how samples and data were to be stored
to ensure confidentiality of the information.
Discussion
A wide range of protocols was reviewed, varying in purpose,
design and health conditions studied. Based on these results,
investigators should adhere closely to the submission
formalities with regard to financial disclosure. Protocols should
reflect scientific rigour, a clear description of the methodology
and data analysis. It should be clearly indicated that the
welfare of subjects is a primary concern and that adequate,
readily accessible insurance cover is provided to the
participants.
Informed consent documentation should be comprehensive
and written in language at an appropriate level, with minimal
recourse to technical terms. Guidelines are available regarding
essential information that should be included in informed
consent documents, including that of the Medical Research
Council of South Africa,8 which researchers should  consult to
prevent requests for amendments. 
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